Literature DB >> 10210830

A comparison of the spread of three formulations of botulinum neurotoxin A as determined by effects on muscle function.

.   

Abstract

The purpose of these experiments was to compare the spread of three formulations of botulinum neurotoxin A. A gelatin/phosphate buffer (C), DysportR (D {0.5 U}, BotoxR (B {0.167 U}), or a purified preparation of botulinum neurotoxin A [Bont A] (BA {0.5 U}) was injected into the tibialis anterior of male, Wistar rats. After 4 days, the adjacent extensor digitorum longus muscle was isolated in situ and the nerve was maximally stimulated to determine contractile properties and the rate of fatigue. There were no differences in body or muscle weights between any of the groups after 4 days of treatment. Maximal twitch and tetanic tensions were decreased reverse similar 25% (p < 0.05) in all treatment groups compared to C. In addition, rate of tension development was significantly less in all treatment groups compared to C but one-half relaxation time and time to peak tension were not different between any groups. Fatigue of the muscle was significantly faster in all groups compared to C but there was no difference between treatment groups. These data indicated that botulinum toxin A injected intramuscularly was likely to spread to adjacent muscles but that the spread was not different between the three formulations tested. The effect of the spread ranged from a slight to a severe reduction in maximal tension but this did not occur in all animals studied. Copyright Rapid Science Ltd

Entities:  

Year:  1998        PMID: 10210830     DOI: 10.1046/j.1468-1331.1998.520181.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  10 in total

Review 1.  Botulinum neurotoxin - from laboratory to bedside.

Authors:  K A Foster; H Bigalke; K R Aoki
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

2.  Influence of injection of Chinese botulinum toxin type A on the histomorphology and myosin heavy chain composition of rat gastrocnemius muscles.

Authors:  Bin Hong; Min Chen; Xing-yue Hu
Journal:  J Zhejiang Univ Sci B       Date:  2013-11       Impact factor: 3.066

3.  Botulinum toxin pretreatment augments the weakening effect of injection with ricin-mAb35 in rabbit extraocular muscle.

Authors:  Stephen P Christiansen; Brian C Anderson; Linda K McLoon
Journal:  J AAPOS       Date:  2008-02-07       Impact factor: 1.220

4.  Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?

Authors:  Jürgen Frevert; Dirk Dressler
Journal:  Biologics       Date:  2010-12-09

5.  Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm.

Authors:  Juwan Park; Michael S Lee; Andrew R Harrison
Journal:  Clin Ophthalmol       Date:  2011-06-01

6.  A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins.

Authors:  Joohi Jimenez-Shahed
Journal:  Neuropsychiatr Dis Treat       Date:  2011-12-23       Impact factor: 2.570

7.  Efficacy of Onabotulinum Toxin A (Botox) versus Abobotulinum Toxin A (Dysport) Using a Conversion Factor (1 : 2.5) in Treatment of Primary Palmar Hyperhidrosis.

Authors:  Hanan Mohamed El Kahky; Heba Mahmoud Diab; Dalia Gamal Aly; Nehal Magdi Farag
Journal:  Dermatol Res Pract       Date:  2013-10-22

Review 8.  Botulinum toxin type A products are not interchangeable: a review of the evidence.

Authors:  Mitchell F Brin; Charmaine James; John Maltman
Journal:  Biologics       Date:  2014-10-06

Review 9.  Neurophysiological Measures of Efficacy and Safety for Botulinum Toxin Injection in Facial and Bulbar Muscles: Special Considerations.

Authors:  Mohammad Alimohammadi; Anna Rostedt Punga
Journal:  Toxins (Basel)       Date:  2017-10-30       Impact factor: 4.546

10.  Immunogenicity of botulinum toxin.

Authors:  Syeo Young Wee; Eun Soo Park
Journal:  Arch Plast Surg       Date:  2022-01-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.